A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61P 35/00 (2006.01) A61P 37/02 (2006.01)
Patent
CA 2533918
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
La présente invention concerne l'utilisation d'anticorps monoclonaux anti rhésus D, chimériques, humanisés ou humains qui sont produits dans des lignées cellulaires sélectionnées, lesdits anticorps provoquant une forte activité ADCC ainsi qu'une forte sécrétion de cytokines et d'interleukines, pour traiter les sous populations de patients dits « faibles répondeurs » présentant le polymorphisme du CD16 FCGR3A-158F homozygotes ou hétérozygotes FCGR3A- 158V/F.
Bihoreau Nicolas
Bourel Dominique
de Romeuf Christophe
Gaucher Christine
Jorieux Sylvie
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
Lfb Biotechnologies
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Use of adcc-optimized antibodies for treating weak patients does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of adcc-optimized antibodies for treating weak patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of adcc-optimized antibodies for treating weak patients will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1791855